Please assess the completion status of the following clinical trial:

Trial Title: Cannabidiol: a Novel Intervention for Cannabis Use Problems?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Aged between 16 and 60 years old.~* Meet DSM-5 criteria for moderate cannabis use disorder (≥4 DSM-5 criteria)~* Express desire to quit using cannabis within the next four weeks,~* Have ≥1 previous failed quit attempt.~* Smoke tobacco with cannabis,~* Test positive for recent cannabis use according to urine analysis,~* Vital signs within healthy limits and have capacity to give consent~Exclusion Criteria:~* Not willing to use effective contraception from when consent is taken to 6 weeks after treatment has stopped~* Positive pregnancy test or breastfeeding~* Allergies to the Investigational Medicinal Product (IMP) or placebo and its excipients~* \>twice/month use of other illicit drugs~* Outside normal Body Mass Index (BMI)~* A physical health problem deemed clinically significant~* The use of current prescribed psychotropic drugs~* Current or prior self-reported diagnosis of a psychotic disorder~* Non-English speakers due to verbal assessments.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Cannabidiol 200mg Oral (Type: EXPERIMENTAL): None
- Cannabidiol 400mg Oral (Type: EXPERIMENTAL): None
- Cannabidiol 800mg Oral (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).